Proton Pump Inhibitors

Lars Olbe (Herausgeber)

Buch | Softcover

X, 251 Seiten

2013
Springer Basel (Verlag)
978-3-0348-9777-8 (ISBN)

Artikel merken

Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists.

The discovery and development of the proton pump inhibitor.- The discovery and development of the proton pump inhibitor.- Mechanism of action.- The gastric H, K ATPase.- Inhibition of the gastric proton pump.- The Pharmacology of proton pump inhibitors.- Inhibition of gastric acid secretion.- Consequences of gastric acid inihibition in animals.- Consequences of gastric acid inhibition in man.- The acid tolerance of Helicobacter pylori.- Interactions of proton pump inhibitors and Helicobacter pylori in vivo.- Comparison of different proton pump inhibitors.- Pharmaceutical considerations.- Pharmaceutical considerations.- Clinical experience with proton pump inhibitors.- Helicobacter pylori infection and peptic ulcer disease.- Non-steroidal anti-inflammatory drug-associated ulcers.- Zollinger-Ellison syndrome.- Gastro-oesophageal reflux disease.- Socio-Economic impact of acid-related diseases.- Socio-economic impact of acid-related diseases.

Erscheint lt. Verlag	3.10.2013
Reihe/Serie	Milestones in Drug Therapy
Zusatzinfo	X, 251 p.
Verlagsort	Basel
Sprache	englisch
Maße	170 x 244 mm
Gewicht	466 g
Themenwelt	Medizin / Pharmazie ► Allgemeines / Lexika
Schlagworte	Diseases • Drug • Helicobacter pylori • pharmacology • quality of life • Research • therapy
ISBN-10	3-0348-9777-4 / 3034897774
ISBN-13	978-3-0348-9777-8 / 9783034897778
Zustand	Neuware